EUVIMEDEUVIMED entdecken
Open Access

Medications for OUD: Extended-Release Naltrexone

A Benjamin Srivastava

Current Addiction Reports · 06.02.2025 · 12 (1)

DOI: 10.1007/s40429-025-00636-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Addiction Reports, online erschienen am 06.02.2025. Verfasst von A Benjamin Srivastava. Beteiligte Einrichtung: Division on Substance Use Disorders, Department of Psychiatry, Columbia University Irving Medical Center, New York, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAAA NIH HHS, National Institute on Alcohol Abuse and Alcoholism.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose of Review: Opioid use disorder (OUD) is a chronic, relapsing illness associated with significant morbidity and mortality. Extended-release naltrexone (XR-NTX) is an evidence-based pharmacotherapeutic agent for the treatment of OUD. This review aims at reviewing the extant literature support XR-NTX, its limitations, and providing directions for future research. Recent Findings: XR-NTX has been shown to be comparable to treatment with buprenorphine in head-to-head randomized controlled trials. XR-NTX has demonstrated clinical efficacy in several vulnerable populations with OUD including adolescents, criminal justice offenders, and patients infected with human immunodeficiency virus (HIV). XR-NTX has demonstrated efficacy for other substance use disorders including alcohol use disorder (AUD) and, when combined with bupropion, methamphetamine use disorder. Challenges to treatment include managing opioid withdrawal symptoms during XR-NTX induction as well relapse and overdose upon treatment discontinuation. Summary: XR-NTX is a first-line pharmacotherapeutic option when treating opioid use disorder with demonstrated efficacy; challenges include supporting the patient during withdrawal to facilitate successful induction and encouraging compliance to mitigate risks of relapse and overdose.

Schlagwörter

Stichwörter der Autor:innen

AntagonistExtended-releaseNaltrexoneOpioid use disorderRelapse prevention

Autor:innen und Institutionen

  • Division on Substance Use Disorders, Department of Psychiatry, Columbia University Irving Medical Center, New York, USA.

Förderung

  • NIAAA NIH HHS
  • National Institute on Alcohol Abuse and Alcoholism

Zitieren

APA

Srivastava, A. B. (2025). Medications for OUD: Extended-Release Naltrexone. Current Addiction Reports, 12(1). https://doi.org/10.1007/s40429-025-00636-9

Vancouver

Srivastava AB. Medications for OUD: Extended-Release Naltrexone. Current Addiction Reports. 2025;12(1). doi:10.1007/s40429-025-00636-9

BibTeX
@article{Srivastava2025,
  author = {Srivastava, A Benjamin},
  title = {Medications for OUD: Extended-Release Naltrexone},
  journal = {Current Addiction Reports},
  year = {2025},
  volume = {12},
  number = {1},
  doi = {10.1007/s40429-025-00636-9}
}
Kostenlos starten →